Biomedical Research and Innovation Institute of Cadiz (INiBICA), Research Unit, Puerta del Mar University Hospital, Cádiz, Spain.
Neuropsychopharmacology and Psychobiology Research Group, Universidad de Cádiz, Cádiz, Spain.
Int J Neuropsychopharmacol. 2024 Feb 1;27(2). doi: 10.1093/ijnp/pyae002.
Cannabis use is a risk factor of psychiatric illness, such as bipolar disorder type-I (BDI). Indeed, cannabis use strongly influences the onset and clinical course of BDI, although the biological mechanisms underlying this interaction remain unknown. Therefore, we have reviewed the biological mechanisms affected by cannabis use that may trigger BD.
A systematic review was carried out of articles in which gene expression was studied in cannabis users or human-derived cells exposed to tetrahydrocannabinol (THC) or cannabidiol (CBD). A second systematic review was then performed to identify articles in which gene expression was studied in BDI samples, highlighting those that described alterations to the same molecular and cellular mechanisms affected by cannabis/THC/CBD.
The initial search identified 82 studies on cannabis and 962 on BDI. After removing duplicates and applying the inclusion/exclusion criteria, 9 studies into cannabis and 228 on BDI were retained. The molecular and cellular mechanisms altered by cannabis use or THC/CBD exposure were then identified, including neural development and function, cytoskeletal function, cell adhesion, mitochondrial biology, inflammatory related pathways, lipid metabolism, the endocannabinoid system, the hypocretin/orexin system, and apoptosis. Alterations to those activities were also described in 19 of 228 focused on BDI.
The biological mechanisms described in this study may be good candidates to the search for diagnostic biomarkers and therapeutic targets for BDI. Because cannabis use can trigger the onset of BD, further studies would be of interest to determine whether they are involved in the early development of the disorder, prompting early treatment.
大麻使用是精神疾病的一个风险因素,如双相情感障碍 I 型(BDI)。事实上,大麻使用强烈影响 BDI 的发病和临床过程,尽管这种相互作用的生物学机制尚不清楚。因此,我们回顾了受大麻使用影响的可能引发 BDI 的生物学机制。
对大麻使用者或暴露于四氢大麻酚(THC)或大麻二酚(CBD)的人源细胞中基因表达进行研究的文章进行了系统回顾。然后进行了第二次系统回顾,以确定研究 BDI 样本中基因表达的文章,突出描述受大麻/THC/CBD 影响的相同分子和细胞机制发生变化的文章。
最初的搜索确定了 82 项关于大麻的研究和 962 项关于 BDI 的研究。在去除重复项并应用纳入/排除标准后,保留了 9 项关于大麻的研究和 228 项关于 BDI 的研究。然后确定了大麻使用或 THC/CBD 暴露改变的分子和细胞机制,包括神经发育和功能、细胞骨架功能、细胞黏附、线粒体生物学、炎症相关途径、脂质代谢、内源性大麻素系统、下丘脑分泌素/食欲素系统和细胞凋亡。在 228 项专注于 BDI 的研究中也描述了这些活动的改变。
本研究中描述的生物学机制可能是寻找 BDI 诊断生物标志物和治疗靶点的良好候选者。由于大麻使用会引发 BDI 的发作,因此进一步的研究将有助于确定它们是否参与该疾病的早期发展,从而促使早期治疗。